We serve Chemical Name:2,5-Dimethyl-1,3-thiazole-4-carboxylic acid CAS:113366-73-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,5-Dimethyl-1,3-thiazole-4-carboxylic acid
CAS.NO:113366-73-7
Synonyms:2,5-Dimethylthiazole-4-carboxylic acid;4-Thiazolecarboxylicacid,2,5-dimethyl;2,5-dimethyl-4-thiazolecarboxylic acid
Molecular Formula:C6H7NO2S
Molecular Weight:157.19000
HS Code:2934100090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:78.43000
Exact Mass:157.02000
LogP:1.45810
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2,5-Dimethylthiazole-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,5-dimethyl-4-thiazolecarboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,5-dimethyl-4-thiazolecarboxylic acid Use and application,2,5-Dimethylthiazole-4-carboxylic acid technical grade,usp/ep/jp grade.
Related News: At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity. 2,5-Dimethyl-1,3-thiazole-4-carboxylic acid manufacturer Over the years, large international pharmaceutical companies have gradually focused on the research and development and sales of patented drugs, and have gradually outsourced traditional products. Among them, most of the contractors are pharmaceutical companies in emerging countries. 2,5-Dimethyl-1,3-thiazole-4-carboxylic acid supplier At present, API companies basically use multi-functional and multi-purpose workshops, and the main equipment uses multi-functional reactors to achieve flexible utilization of production capacity. 2,5-Dimethyl-1,3-thiazole-4-carboxylic acid vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2,5-Dimethyl-1,3-thiazole-4-carboxylic acid factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?
